Oxford Archives - ARC Group

News

DEPUTY MAYOR HOWARD DAWBER OFFICIALLY OPENS LEAP – A NEW SHARED LAB FACILITY FOR EARLY-STAGE COMPANIES FROM IMPERIAL INCUBATOR – AT ARC WEST LONDON

Terumo to acquire OrganOx in landmark deal expanding opportunities for organ transplantation worldwide

Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale

ARC OXFORD MEMBER WINS MACROBERT AWARD FOR WORLD-FIRST LIFE-SAVING TECHNOLOGY

ARC Oxford Breaks Ground on 105,000 sq. ft Landmark Lab & Office Development

ARC’s campuses receive ‘Workspace of the Year’ title at the 2025 Hustle Awards

Groundbreaking UK Prostate Test May Eliminate Biopsies for Most Men

ARC wins at The Life Sciences and Research Clusters Awards 2025

ARC shortlisted for Workspace of the Year at Hustle Awards 2025

FluoRok Expands at Brookfield’s ARC Oxford Campus

ARC shortlisted for two awards at the Life Sciences and Research Clusters Awards 2025

Brookfield’s ARC Uxbridge Campus Outperforms 5-year average uptake for the area following surge in high-profile leases

IMPERIAL INCUBATOR, IMPERIAL COLLEGE HEALTHCARE NHS TRUST AND ARC WEST LONDON ANNOUNCE PARTNERSHIP

Sir Patrick Vallance Meets Science & Innovation Leaders at ARC Oxford

ARC and Harwell Campus Announce Appointment of Jim Stretton as Managing Director

Rishi Sunak visits Oxford BioDynamics on Cancer Crusade

ARC support’s Government plan to create British rival to Silicon Valley

ARC recognised by British Diversity Awards for its inclusive practices

The Next Stop is ARC Uxbridge for BYD

ARC OXFORD GETS TOP RATING FROM TRIPADVISOR GROUP AS IT RELOCATES TO THE CAMPUS

SUNTORY SELECTS ARC UXBRIDGE AS NEW HEAD OFFICE

ARC’S HARWELL CAMPUS NAMED UK’S MOST SUCCESSFUL SCIENCE CAMPUS

ARC joins sector calls for the Government to protect R&D funds in the autumn budget

FluoRok raises £7.7m to transform the safety and sustainability of fluorochemical production

Daiichi Sankyo gets go-ahead for acute myeloid leukaemia treatment

TRADITIONAL LAB DESIGN NOT ADDRESSING SENSORY PROCESSING NEEDS OF NEURODIVERSE MINDS

Epsilogen completes £12.5 million Series B financing expansion

The Science of Business Returns

YELLOWSTONE BIOSCIENCES LAUNCHES AT ARC OXFORD

ARC supports the drive to revive Oxford-Cambridge high-tech growth plan

Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy.

you’ve seen 30 of 73 News

1
2
3